USPTO Examiner ADLAM CHANTAL PETA GAYE - Art Unit 1622

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19231354OPHTHALMIC COMPOSITIONS FOR TREATMENT OF OCULAR SURFACE DAMAGE AND SYMPTOMS OF DRYNESSJune 2025March 2026Abandon910NoNo
189498014H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDSNovember 2024January 2026Abandon1411NoNo
18614993COMPOSITIONS AND METHODS FOR TREATING HYPERTENSIONMarch 2024March 2025Abandon1220NoNo
18496137GLP-1R MODULATING COMPOUNDSOctober 2023October 2025Allow2411NoNo
18238091PHARMACEUTICAL COMPOSITIONAugust 2023January 2026Abandon2851YesNo
18137893NOVEL QUINOLIN-2-YL NITRONES USEFUL FOR THE PREVENTION AND/OR TREATMENT OF NEURODEGENERATIVE DISEASESApril 2023November 2025Abandon3021NoYes
18090647PHARMACEUTICAL COMPOSITIONDecember 2022January 2025Abandon2421YesNo
18077844SALVINORIN COMPOSITIONSDecember 2022September 2024Abandon2111NoNo
17937758METHODS AND COMPOSITIONS FOR TREATING CARDIOMYOPATHY AND HEART FAILUREOctober 2022January 2026Abandon3941YesNo
17954557PHARMACEUTICAL COMPOSITIONS CONTAINING PARACETAMOL DERIVATIVES AND USE THEREOFSeptember 2022June 2025Allow3221YesNo
17931456CRYSTALLINE FORM OF TLR8 AGONISTSeptember 2022September 2025Allow3610NoNo
17903216CHEMICAL COMPOUNDSSeptember 2022October 2025Abandon3801NoNo
17802908METHODS AND MATERIALS FOR DIAGNOSIS AND TREATMENT OF NEURONAL DISORDERAugust 2022March 2026Allow4210NoNo
17892620METHOD FOR TREATMENT OF ROSACEA IN PATIENTS AGED 35-64 YEARSAugust 2022February 2025Abandon3020NoNo
17795929COMPOUNDS AND USES THEREOFJuly 2022January 2026Allow4211NoNo
17874984NOVEL COMPOSITIONS INCLUDING CANNABIS AND AVOCADO/SOYBEAN UNSAPONIFIABLES AND METHODS OF USEJuly 2022March 2026Allow4420NoNo
17857991COMPOSITIONS AND METHODS FOR TREATING HYPERTENSIONJuly 2022February 2024Allow2010YesNo
17853035METHOD FOR ALLEVIATING ARTHRITIS USING EPIDERMAL GROWTH FACTORJune 2022November 2025Abandon4140NoNo
1783505118-MC FOR TREATING OBESITYJune 2022June 2024Abandon2520NoNo
17832566BVP8 PROTEIN FOR KILLING TETRANYCHID MITES AND USE THEREOFJune 2022July 2023Allow1400NoNo
17831276USE OF AMITRIPTYLINE AND/OR ONE OF THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS A PRESERVATIVEJune 2022June 2024Abandon2420YesNo
17737218RAS INHIBITORSMay 2022September 2024Allow2911NoNo
17770924Mitochondria-Targeted Atovaqone: A More Potent and More Effective Antitumor, Antimicrobial, and Antimalarial DrugApril 2022November 2025Allow4300NoNo
17691260CONTACT LENS TREATING SOLUTIONMarch 2022January 2026Allow4631NoYes
17620095ISOXAZOLINE PARASITICIDE FORMULATIONS AND METHODS FOR TREATING BLEPHARITISDecember 2021March 2026Abandon5120NoNo
17552792HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORSDecember 2021January 2026Allow4911NoNo
17538821CRYSTALLINE FORMS OF NEUROTROPHIN MIMETIC COMPOUNDS AND THEIR SALTSNovember 2021September 2025Abandon4501NoNo
17614530COMPOSITIONS FOR DELIVERY OF LADOSTIGILNovember 2021March 2025Abandon4010NoNo
17595796FUSED HETEROCYCLIC DERIVATIVES AS ANTIVIRAL AGENTSNovember 2021June 2025Abandon4310NoNo
17612889TREATMENT OF OCULAR DISEASENovember 2021January 2026Abandon5020YesNo
17610787TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUSNovember 2021February 2026Abandon5121NoNo
176059754H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDSOctober 2021March 2026Allow5221NoNo
17600587FUSED POLYCYCLIC PYRIDONE COMPOUNDS AS INFLUENZA VIRUS REPLICATION INHIBITORSSeptember 2021July 2025Abandon4601NoNo
17600178COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD)September 2021July 2025Abandon4601NoNo
17441082PESTICIDALLY ACTIVE AZOLE AMIDE COMPOUNDSSeptember 2021May 2025Abandon4401NoNo
17458031SYNTHESIS OF POZIOTINIB DERIVATIVEAugust 2021May 2024Abandon3210NoNo
17429968SOLID STATE FORMS OF N-[2-(2-{4-[2-(6,7-DIMETHOXY-3,4-DIHYDRO-2(1H)-ISOQUINOLINYL)ETHYL]PHENYL}-2H-TETRAZOL-5-YL)-4,5- DIMETHOXYPHENYL]-4-OXO-4H-CHROMENE-2-CARBOXAMIDE AND OF ITS MESYLATE SALTAugust 2021May 2025Allow4510YesNo
17430025CANCER TREATMENTAugust 2021March 2026Allow5510NoNo
17429301COMPOUNDS AND METHODS FOR THE TREATMENT OF PKR-ASSOCIATED DISEASESAugust 2021July 2025Allow4710NoNo
17428396METHODS AND COMPOSITIONS FOR MODULATING BLOOD-BRAIN BARRIERAugust 2021February 2025Abandon4301NoNo
17415279USE OF OLANZAPINE FOR TREATMENT OF PARP-INHIBITOR-INDUCED NAUSEAJune 2021October 2024Abandon4010NoNo
17413139SMALL MOLECULE INHIBITORS OF THE ANDROGEN RECEPTOR ACTIVITY AND/OR EXPRESSION AND USES THEREOFJune 2021September 2025Allow5121YesNo
17296073COMPOSITION COMPRISING A CHOLINE SALT OF A FATTY ACID AND ITS USE AS A FUNGICIDEMay 2021August 2025Allow5130YesYes
17325934HETEROCYCLIC COMPOUNDSMay 2021June 2025Allow4911NoNo
17292663CRYSTALLINE FORMS OF A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND AND USE THEREOF AS P2X3 MODULATORMay 2021June 2025Allow4930NoNo
17291547FLAVONOID DELIVERY SYSTEMMay 2021July 2024Abandon3910NoNo
17056947THERAPEUTIC OR PREVENTING AGENT FOR MULTIPLE SCLEROSIS INCLUDING INDOLE COMPOUNDApril 2021July 2025Allow5520NoNo
17287901Next Generation Synthetic Transcription FactorsApril 2021July 2025Abandon5120NoNo
17286799TREATMENT OF NEUROLOGICAL DISEASEApril 2021June 2025Abandon5021NoNo
17281395INDOLE AHR INHIBITORS AND USES THEREOFMarch 2021August 2024Abandon4001NoNo
17278585OPHTHALMIC COMPOSITIONS FOR TREATMENT OF OCULAR SURFACE DAMAGE AND SYMPTOMS OF DRYNESSMarch 2021February 2026Abandon5940NoNo
17276972QUINOLINE DERIVATIVE USED FOR TREATING SMALL CELL LUNG CANCERMarch 2021September 2025Abandon5440NoNo
17276920TLR8 AGONISTMarch 2021April 2024Allow3701YesNo
17276375PROPHYLACTIC AGENT FOR SPONTANEOUS CANCERSMarch 2021March 2025Abandon4830YesNo
17187877LIQUID FORMULATION OF BIPHENYL-CONTAINING COMPOUND AND APPLICATION THEREOFFebruary 2021July 2025Allow5240YesNo
17272129MACROCYCLIC CHELATES AND USES THEREOFFebruary 2021September 2025Abandon5421NoNo
17173069NOVEL USES OF DUAL NK-1 /NK-3 RECEPTOR ANTAGONISTS FOR TREATING SEX-HORMONE DISEASESFebruary 2021February 2024Allow3630NoNo
17265883INHIBITING DEUBIQUITINASE USP25 AND USP28February 2021November 2024Allow4511NoNo
17265982TISSUE TRANSGLUTAMINASE MODULATORS FOR MEDICINAL USEFebruary 2021November 2025Abandon5831NoNo
17146327FUROQUINOLINEDIONES AS INHIBITORS OF TDP2January 2021January 2024Allow3711NoNo
16972368METHOD OF ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF 5-[[4-[2-[5-(1-HYDROXYETHYL)PYRIDIN-2-YL]ETHOXY]PHENYL]METHYL]-1,3-THIAZOLIDINE-2,4-DIONEDecember 2020March 2026Allow6050NoYes
17045392TREATMENT OF CANCER BY GUANIDINIUM DERIVATIVESOctober 2020November 2024Abandon4901NoNo
16987092ACRIDINIUM ESTER-CONTAINING COMPOUNDS AND METHODS OF USING THE SAME FOR CHEMILUMINESCENCE-BASED ONE-COLOR SEQUENCINGAugust 2020March 2025Allow5551YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ADLAM, CHANTAL PETA-GAYE.

Strategic Value of Filing an Appeal

Total Appeal Filings
2
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
2
(100.0%)
Filing Benefit Percentile
0.2%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ADLAM, CHANTAL PETA-GAYE - Prosecution Strategy Guide

Executive Summary

Examiner ADLAM, CHANTAL PETA-GAYE works in Art Unit 1622 and has examined 39 patent applications in our dataset. With an allowance rate of 43.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.

Allowance Patterns

Examiner ADLAM, CHANTAL PETA-GAYE's allowance rate of 43.6% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ADLAM, CHANTAL PETA-GAYE receive 1.72 office actions before reaching final disposition. This places the examiner in the 36% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ADLAM, CHANTAL PETA-GAYE is 49 months. This places the examiner in the 6% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +39.5% benefit to allowance rate for applications examined by ADLAM, CHANTAL PETA-GAYE. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 20.7% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 44.4% of cases where such amendments are filed. This entry rate is in the 68% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 92% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 200.0% are granted (fully or in part). This grant rate is in the 98% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.